Skip to Main Content

Advertisement

Skip Nav Destination

Richard Stone, MD: New FLT3 Inhibitor Crenolanib Shows Promise in FLT3-Mutated AML

December 30, 2021
On location

The FLT3 inhibitor crenolanib, when added to standard induction chemotherapy, was associated with high rates of minimal residual disease negativity in patients with FLT3-mutated acute myeloid leukemia. Dr. Stone shares results from the ongoing phase II trial.

Advertisement

Connect with us:

CURRENT ISSUE
August 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement